207 related articles for article (PubMed ID: 16678934)
1. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
[TBL] [Abstract][Full Text] [Related]
2. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia.
Abdo WF; van de Warrenburg BP; Munneke M; van Geel WJ; Bloem BR; Kremer HP; Verbeek MM
Neurology; 2006 Aug; 67(3):474-9. PubMed ID: 16894110
[TBL] [Abstract][Full Text] [Related]
3. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.
Petzold A; Thompson EJ; Keir G; Quinn N; Holmberg B; Dizdar N; Wenning GK; Rascol O; Tolosa E; Rosengren L
J Neurol Sci; 2009 Apr; 279(1-2):76-9. PubMed ID: 19195665
[TBL] [Abstract][Full Text] [Related]
6. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease.
van Eijk JJ; van Everbroeck B; Abdo WF; Kremer BP; Verbeek MM
J Alzheimers Dis; 2010; 21(2):569-76. PubMed ID: 20555148
[TBL] [Abstract][Full Text] [Related]
7. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
[TBL] [Abstract][Full Text] [Related]
8. Serum prolactin levels in Parkinson's disease and multiple system atrophy.
Winkler AS; Landau S; Chaudhuri KR
Clin Auton Res; 2002 Oct; 12(5):393-8. PubMed ID: 12420085
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
[TBL] [Abstract][Full Text] [Related]
10. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls.
Pijnenburg YA; Janssen JC; Schoonenboom NS; Petzold A; Mulder C; Stigbrand T; Norgren N; Heijst H; Hack CE; Scheltens P; Teunissen CE
Dement Geriatr Cogn Disord; 2007; 23(4):225-30. PubMed ID: 17290105
[TBL] [Abstract][Full Text] [Related]
11. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
[TBL] [Abstract][Full Text] [Related]
13. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy.
Abdo WF; van de Warrenburg BP; Kremer HP; Bloem BR; Verbeek MM
Parkinsonism Relat Disord; 2007 Dec; 13(8):480-2. PubMed ID: 17448720
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
Holmberg B; Johnels B; Blennow K; Rosengren L
Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.
Pellecchia MT; Pivonello R; Salvatore E; Faggiano A; Barone P; De Michele G; Lombardi G; Colao A; Filla A
Clin Endocrinol (Oxf); 2005 Apr; 62(4):428-33. PubMed ID: 15807873
[TBL] [Abstract][Full Text] [Related]
16. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
Abdo WF; De Jong D; Hendriks JC; Horstink MW; Kremer BP; Bloem BR; Verbeek MM
Mov Disord; 2004 May; 19(5):571-9. PubMed ID: 15133823
[TBL] [Abstract][Full Text] [Related]
18. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.
Bech S; Hjermind LE; Salvesen L; Nielsen JE; Heegaard NH; Jørgensen HL; Rosengren L; Blennow K; Zetterberg H; Winge K
Parkinsonism Relat Disord; 2012 Jan; 18(1):69-72. PubMed ID: 21873100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
